Senate Grills Pharma CEOs Over High Drug Prices
Pharmaceutical CEOs faced tough questioning from senators over the sky-high drug prices in the U.S., with particular focus on the stark price disparities between the U.S. and other countries for the same medications. The CEOs defended the high prices, citing the value the medications provide and the need for investment in new medicines, while also pointing fingers at insurance companies and middlemen for high out-of-pocket costs. Senators expressed skepticism and concern over the impact of aggressive policies on drug investments and access, and grilled the executives on their efforts to prevent generics from entering the market.